SANIONNasdaq StockholmHealth CareIFRS · SEK

Saniona

Saniona is a Swedish clinical-stage biopharmaceutical company focused on discovering and developing medicines that modulate ion channels. Its work centers on proprietary research programs, partnered drug candidates, and a pipeline aimed at neurological and psychiatric disorders, with operations anchored in Sweden and Denmark and a subsidiary structure that also includes Italy.

Ask about the company
Revenue434m SEK
+29.8 %y/y
Operating profit (EBIT)271m SEK
+12.0 %y/y
EBIT margin62.4%
−9.9 ppy/y
Net income247m SEK
+31.0 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-600-400-2000200400600m SEK2020: 8.2 m SEK2020: EBIT -159 m SEK20202021: 10 m SEK2021: EBIT -412 m SEK20212022: 15 m SEK2022: EBIT -226 m SEK20222023: 17 m SEK2023: EBIT -81 m SEK20232024: 335 m SEK2024: EBIT 242 m SEK20242025: 434 m SEK2025: EBIT 271 m SEK2025434271
RevenueOperating profit (EBIT)
Ask Clarifo about Saniona

Business

Share of revenue
Proprietary pipeline programs45 %

Internal drug candidates in preclinical and clinical development for CNS and related diseases.

Partnered licensing programs35 %

Programs licensed to pharmaceutical partners with milestone and royalty potential.

Research platform and database10 %

IONBASE and related discovery capabilities used to generate and optimize compounds.

Spinouts and collaborations10 %

Externalized assets and research collaborations built from Saniona’s ion channel expertise.

Customers

Saniona’s direct counterparties are primarily pharmaceutical and biotechnology companies that license its programs or enter collaboration agreements around specific drug candidates. The company also serves research and development partners that value its ion channel discovery platform and compound library. For its own pipeline, the eventual customers are patients, physicians, and healthcare systems in neurological and psychiatric disease areas, but commercialization is typically expected through partners.

Pharmaceutical licensing partners

Buy rights to Saniona programs such as SAN2355 or SAN711 because they want differentiated CNS assets and milestone/royalty economics.

Biotechnology collaboration partners

Work with Saniona on discovery or development projects to access ion channel chemistry, biology, and screening capabilities.

Future end patients and prescribers

Use the medicines if approved, especially in epilepsy, depression, and other neurological disorders.

Research and development counterparties

Engage Saniona for platform-based discovery work, compound libraries, and spinout opportunities.

Strategy

Saniona’s strategy is to create value through ion channel science, advancing selected internal candidates while partnering other programs to larger pharmaceutical companies. The company is also building a broader pipeline in epilepsy, depression, and other CNS indications, using partnerships to validate assets and fund development. This model is designed to combine scientific optionality with external development leverage and future milestone and royalty economics.

Advance proprietary pipeline candidatesMedium term

Internal programs create long-term upside if they reach clinical proof-of-concept and approval.

Monetize partnered assets through licensingShort term

Partnerships reduce development burden and can generate upfront, milestone, and royalty income.

Leverage the ion channel discovery platformLong term

IONBASE and related capabilities are the source of new candidates and collaboration opportunities.

Geography

Saniona is headquartered in Sweden but most of its operating activity is conducted through Saniona A/S in Denmark, with additional presence in Italy through Saniona Italy Srl. Its business is international by design: partnership revenue is denominated mainly in EUR, USD, and DKK, and the company targets regulatory and commercial pathways in the US and Europe. That geographic mix creates exposure to currency movements, cross-border collaboration, and differing regulatory regimes.

Risks

Saniona faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, regulatory delays, competition, and dependence on partners for development and commercialization. Its international structure also creates foreign exchange exposure, while funding needs and collaboration timing can materially affect execution.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Dependence on collaboration agreements1Clinical development failure or delay2Competition from earlier or better therapies3Future financing needs4Foreign exchange exposure5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Dependence on collaboration agreementsImpact: HighLikelihood: High

    A meaningful part of value creation depends on third-party partners advancing licensed programs and paying milestones/royalties.

    Exposure: Licensing and partnership portfolio

  2. Clinical development failure or delayImpact: HighLikelihood: Medium

    Drug candidates can fail in preclinical or clinical testing, which would reduce pipeline value and postpone partnering or approval.

    ExposureSAN2219SAN2465SAN2668Partnered assets
  3. Competition from earlier or better therapiesImpact: HighLikelihood: Medium

    Other companies may commercialize similar or superior products sooner, limiting Saniona’s partnering and commercialization prospects.

    Exposure: CNS and ion channel drug development

  4. Future financing needsImpact: HighLikelihood: Medium

    As a clinical-stage biotech, Saniona may need additional capital before products generate sustainable operating cash flow.

    Exposure: Pipeline development and corporate overhead

  5. Foreign exchange exposureImpact: MediumLikelihood: Medium

    Operations, costs, and partnership inflows are spread across DKK, EUR, USD, and SEK, creating transaction and translation risk.

    ExposureDenmarkSwedenUSEurope
Ask Clarifo about Saniona

Accounting

Judgemental items
Research and development accruals

Clinical and preclinical costs are estimated before invoices are finalized, affecting expense timing and liabilities.

Impact: Trial-related CRO/CMO costs and project expense recognition

Licensing and milestone revenue recognition

Upfront payments, milestones, and royalties can have different recognition patterns depending on contract terms.

Impact: Reported revenue timing and comparability across periods

Going concern and liquidity assessment

Clinical-stage biotech valuation depends on available funding versus future development commitments.

Impact: Balance sheet presentation and investor assessment of runway

Foreign currency translation

Functional currencies differ across the group, so exchange rates affect reported assets, liabilities, and results.

Impact: SEK-reported financial statements

Similar listed companies

Publicly listed companies with a comparable business focus.

Cantargia

CANTA · Health Care

Ionis Pharmaceuticals, Inc

IONS · Pharmaceutical Preparations

Sionna Therapeutics, Inc.

SION · Pharmaceutical Preparations

Sana Biotechnology, Inc.

SANA · Biological Products, (No Diagnostic Substances)

Hansa Biopharma

HNSA · Health Care

Sedana Medical

SEDANA · Health Care

Last updated: 24/09/2026